EPISODE · Jul 22, 2025 · 17 MIN
Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA
from BiotechTV - News · host BiotechTV
He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in general, including what orforglipron might mean for the oral therapy space and why Metsera believes in an oral peptide.
Embed this episode
NOW PLAYING
Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA
0:00
17:46
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 17 minutes long.
When was this BiotechTV - News episode published?
This episode was published on July 22, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!